Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm
This presentation is the property of its rightful owner.
Sponsored Links
1 / 55

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber PowerPoint PPT Presentation


  • 65 Views
  • Uploaded on
  • Presentation posted in: General

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber Bereich Europäische und Internationale Programme FFG – Österreichische Forschungsförderungsgesellschaft. Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

Download Presentation

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm

(7.RP) für Forschung und Entwicklung

Ylva Huber

Bereich Europäische und Internationale Programme

FFG – Österreichische Forschungsförderungsgesellschaft


Inhalt

Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung

Das Programm „IDEAS“

Inhalt


Inhalt1

Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

„Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung

Das Programm „IDEAS“

Inhalt


Budget fp7 f r common approach

Cooperation 32.315

Health6.000

Biotech, Food, Agriculture1.935

Information Society9.120

Nanomaterials Production 3.505

Energy2.300

Environment1.900

Transport4.195

Socio-economic Research 610

Security and Space2.750

Ideas 7.460

People4.728

Capacities 4.267

Budget FP7: für „Common Approach“

Total: 50.521 billion EUR

(incl. Joint Research Centre 1,7 Mrd)


Instrumente im 7 rp

Instrumente im 7. RP


F rderh hen im 7 rp

Abschaffung der Kostenmodelle

Forschung und Entwicklung: Förderung bis zu 75%

Universitäten

Forschungsorganisationen

Öffentliche Einrichtungen

KMU

Unternehmen: 50%

Demonstration: bis zu 50%

Grundlagenforschung: bis zu 100%

Specific Support Actions und Coordination Actions: bis zu 100%

Pauschalen für indirekte Kosten sind möglich

Vereinfachung der Abläufe

Förderhöhen im 7. RP


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Technologieplattformen und Gemeinsame Technologieinitiativen

  • Mobilisierung europäischer Ressourcen im Bereich Forschung, technologische Entwicklung und Innovation durch Zusammenbringen aller Akteure eines definierten Forschungsbereiches (Industrie, KMU, Universitäten, Endverbraucher)

  • Industriegetrieben

  • Gemeinsame Definition und Erstellung einer strategischen Forschungsagenda (mittel- bis langfristig)

    = Input zur Entwicklung der thematischen Programme im 7. RP

  • Einige wenige werden als Gemeinsame Technologieinitiativen (Joint Technology Initiatives) etabliert

  • Neuer Weg zur Realisierung von public-private partnerships auf EU-Ebene mit definierter rechtlicher Struktur


Inhalt2

Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

Ausschreibungsthemen zu „Health“ und „Biotechnologies, Agriculture, Food and Fisheries“

Das Programm „IDEAS“

Nächste Schritte

Inhalt


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Ziele:

  • Verbesserung der Gesundheit der europäischen Bevölkerung

  • Stärkung der europ. Industrie/Firmen im Bereich Gesundheit

  • Blick auf globale Gesundheitsfragen

    (z.B. Epidemien

    Schwerpunkte:

  • Translationale Forschung (Grundlagenforschung  klinische Anwendung)

  • Neue Therapien (Entwicklung und Validierung)

  • Methoden zur Gesundheitsförderung, Krankheitsprävention

  • Diagnostische Instrumente und medizinische Technologien

  • Effiziente Gesundheitssysteme

Thema 1- Gesundheit

(6.050 Mio. Euro)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Biotechnology, generic tools and technologies for human health

2

Translating research for human health

3

4

Optimising the delivery of health care to European Citizens

Other Actions across the Health Theme

Theme 1: HEALTH

(6.000 Mio. €)

Activities


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Biotechnology, generic tools and technologies for human health (1)

High-throughput research

  • Unifying human and model organism genetic variation databases

  • Temporal and spatial proteomics to study biological processes relevant to human health

  • Groundbreaking techniques for DNA sequencing and genotyping

    2. Call:

  • SME-driven collaborative research projects for developing tools and technologies for high-throughput research

    Detection, Diagnosis and Monitoring

  • Development of a hybrid imaging system

  • Novel optical methodologies for detection, diagnosis and monitoring of disease or disease-related processes

  • Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of response to therapy

  • In vivo image-guidance for cell therapy

    2. Call :

  • Standardisation and improvement of pre-analytical procedures for in vitro diagnostics

  • High throughput molecular diagnostics in individual patients for genetic diseases with heterogeneous clinical presentation


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Biotechnology, generic tools and technologies for human health (2)

Predicting suitability, safety and efficacy of therapies

Thema zum Großteil durch Innovative Medicines Initiative (IMI) abgedeckt!

  • Novel alternative testing strategies for use in pharmaceutical discovery and development

  • Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development

  • Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology

  • Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

  • In silico modelling for ADMET outcomes


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Biotechnology, generic tools and technologies for human health (3)

Innovative therapeutic approaches and interventions

  • Development and production of new generation antibodies

  • Innovative approaches for the development of vaccines for young children

  • Immunotherapy of human food allergies

    2.Call:

  • Development of emerging gene therapy tools and technologies for clinical application

  • Stem cell lines forcell-based therapies.

  • Development of stem cell culture conditions.

  • Stem cells for kidney regeneration.

  • Adding value to EU stem cell therapy research: scientific communication and future perspectives.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (1)

2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

Large-scale data gathering

  • Networking biobanking initiatives across Europe: developing standards and norms for existing and future human sample biobanks

  • Molecular epidemiological studies in existing well characterised European (and/or other) population cohorts

  • Comparative studies of genetic variation in humans: towards a reference population in Europe

  • Characterisation and variability of the microbial communities in the Human Body

  • Structure-function analysis of membrane-transporters and channels for the identification of potential drug target sites

  • High throughput analysis of lipids and lipid-protein interactions

  • Genome-wide association studies in mammalian non-rodent models for the identification of genes relevant to human health and disease


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (2)

2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY

  • Systems biology

  • A system approach to eukaryotic unicellular organism biology

  • Modelling of T-cell activation

  • Fundamental approaches to stem cell differentiation

  • Developing an integrated in vitro, in vivo and systems biology modelling approach to understandingapoptosis in the context of health and disease

    2. call:

  • Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases

  • Coordination and Support Actions in large-scale data gathering and systems biology

  • Traditional Chinese Medicine in post-genomic era. Specific International Cooperation Action. Targeted region: China.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (3)

2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING

Brain and related diseases

  • Stroke and mechanisms underlying ischemic brain damage

  • Coding in neuronal assemblies

  • Neurobiologyof anxiety disorders

  • Memory loss: underlying mechanisms and therapy

  • From basic spinal mechanisms to spinal cord disease and trauma.

  • Neuron-glia interactions in health and disease

    2. Call:

  • Restorative approaches for therapy of neurodegenerative diseases.

  • From mood disorders to experimental models.

  • Neuronal mechanisms of vision and related diseases.

  • Childhood and adolescent mental disorders. Specific International Cooperation Action. Target regions: Eastern Europe and Central Asia and Western Balkans.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (4)

2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING

Human Development and Ageing

  • Novel approaches to reconstitute normal immune function at old age.

  • Termination of developmental processes and their reactivation in adult life

  • Biomarkers of ageing.

  • Increasing the participation of elderly in clinical trials.

  • Research on human development and/or healthy ageing across the EU


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (5)

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:

TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

Anti-microbial drug resistance including fungal pathogens

2. Call:

  • Novel targets for drugs against Gram negative bacteria.

  • Host-pathogen interactions in infections by Streptococcus pneumoniae.

  • An integrated platform for development and clinical evaluation of point-of-care diagnostic devices for microbial detection, antibiotic susceptibility determination and biomarkers

  • Molecular epidemiology to control nosocomial and community spreading of highly virulent multi-drug resistant strains of bacterial pathogens.

  • Health and economic cost of antimicrobial resistance.

  • Conference on genetic and biochemical tools for postgenomic physiological analysis of Staphylococcus, in particular MRSA.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (6)

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:

TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

HIV, AIDS, malaria and tuberculosis

  • HIV/AIDS Drug Discovery and Preclinical Development

  • Highly innovative approaches for research into host-pathogen interaction in tuberculosis

  • Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria and tuberculosis and of latent tuberculosis infection (LTBI).

  • Addressing knowledge gaps in pregnancy malaria.

  • New HIV Vaccines inducing broadly-reactive neutralising antibodies.

  • 2. Call:

  • Network on HIV and anti-HIV drug resistance

  • HIV and Hepatitis co-infection

  • Blocking the transmission of malaria: the mosquito vector target.

  • European network for study and clinical management of TB drug resistance.

  • Support platform for the development of PRD vaccines

  • Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and European partners. (SICA, Targeted Region: India)

  • Coordination of European research activities with global initiatives, including Public-Private-Partnerships (SICA; Targeted Regions: ICPC).

  • Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious diseases (SICA; Targeted Regions: ICPC).


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (7)

2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:

TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH

Potentially new and re-emerging epidemics

  • Development of broadly protective influenza vaccine candidates.

  • Identifying immunological mechanisms of protection for influenza vaccines

  • Standardisation of immunological assays including surrogate markers for evaluation of new influenza vaccines in clinical trials

  • Innovative point-of-care diagnostic tests for influenza.

  • Development of additional treatment strategies for patients suffering from highly pathogenic influenza.

  • Development of pandemic influenza containment and mitigation strategies.

  • Supporting highly innovative inter-disciplinary research on influenza.

  • Influenza research in collaboration with Asian partners. (SICA, Targeted regions: Asia)

  • 2. Call:

  • Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans.

  • Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health (8)

TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

Cancer

  • Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel diagnosis and therapy strategies.

  • Translating clinical ’omics’-technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients.

  • Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.

  • Novel cancer screening methods.

  • Optimising research on end of life care of cancer patients.

  • Understanding and fighting metastasis.

  • Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy

  • Developing high-throughput bioassays and models for human cancers in lower species.

  • 2. Call:

  • Innovative combination clinical trials for multimodal cancer therapy.

  • Role of inflammation in tumour initiation and progression.

  • Epidemiology of gene-environment interactions involved in carcinogenesis.

  • Translating the hypoxic tumour microenvironment.

  • ERA-NET on optimisation of the use of cancer registries for cancer research purposes

  • Studying cancer aetiology in Latin America. (SICA)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health 9)

TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

Cardiovascular Disease

  • Molecular basis of the inflammatory response and associated vascular remodelling in arteriosclerosis.

  • Vascular remodelling in aneurysmal disease.

  • Combating stroke.

    2. Call:

  • Congenital pathologies affecting the heart.

  • Cell therapies for the treatment of heart ischemia.

  • Organ imaging in CVD.

  • Integrating pharmacogenomic approaches into the treatment of CVD.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health 10)

TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

Diabetes and Obesity

  • Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention.

  • Combined forms of diabetes in children.

  • Insulin resistance as a key factor in the development of diabetes and metabolic syndrome.

  • Pathophysiological mechanisms related to excess fat.

  • A road-map for diabetes research.

    2. Call:

  • Nutritional signals and the development of new diabetes/obesity therapeutic agents.

  • Markers and treatment for diabetic neuropathy complications.

  • Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects.

  • Use of beta cell imaging in diabetes mellitus.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

Translating research for human health 11)

TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES

Rare Diseases

  • Natural course and pathophysiology of rare diseases.

  • Research capacity-building in the field of rare diseases.

    Other Chronic Diseases

  • Osteoarthritis.

  • Inflammatory bowel disease.

  • Osteoporosis: signalling pathways in bone formation and homeostasis.

  • Genetic factors of Osteoporosis.

  • Intervertebral disc degeneration: prevention and repair.

  • Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD).

  • Hearing impairment and degeneration.

  • Impairment of touch and proprioception at old age.

  • Visual impairment and degeneration.

    2. Call:

  • Understanding and combating age-related muscle weakness.

  • Translational research aiming for a treatment of urinary incontinence.

  • Early processes in the pathogenesis of chronic inflammatorydiseases.


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

3

Optimising the delivery of health care to European Citizens (1)

Translating clinical research into clinical practice including better use of

medicines, and appropriate use of behavioural and organisational

interventions and health therapies and technologies

2.call:

  • Implementation of research into healthcare practice

  • Self-medication and patient safety

  • Patient Safety Research Network

  • Improving clinical decision making

  • Better use of medicines.

  • Continuity of clinical care.

  • Patient self-management of chronic disease.

    Quality, solidarity and sustainability of health systems

    2.call:

  • Evaluation of disease management programmes

  • Health systems and long term care of the elderly

  • Mobility of health professionals

  • Health care human resource planning in nursing.

  • Clinician working time and patient safety.

  • Health outcome measures and population ageing.

  • Trends of population health

  • European system of Diagnosis-related groups (DRG)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

3

Optimising the delivery of health care to European Citizens (2)

Enhanced health promotion and disease prevention

2.call:

  • Promoting healthy behaviour in children and adolescents

  • Interventions addressing the gradient of health inequalities

  • Public health interventions addressing the abuse of alcohol.

  • Evaluation of suicide prevention strategies across and within European countries.

  • Improve vaccination coverage

    Horizontal Coordination and Support Actions across “Optimising the Delivery

    of Health Care to European Citizens

    2.call:

  • Disease networks of centres of reference.

  • Effectiveness of health investments.

  • Patient mobility and access to information.

  • Brokering research into policy.

  • A road-map for ageing research.

  • Health Services Research conference

  • Mental health research conference.

  • Public Health intervention research conference


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

3

Optimising the delivery of health care to European Citizens (3)

Specific International Cooperation Actions for Health System Research

2.call:

  • Epidemiological investigations into long-term trends of population health as consequence of socio-economic transitions, including life-style induced health problems. SICA (Mediterranean Partner countries, Russia, Eastern European and Central Asia)

  • Universal and equitable access tohealth care and health financing. SICA (MCP, ACP, Asia and Latin America)

  • Health care intervention research – optimising hospital care. SICA (Western Balkans.)

  • Health care intervention research – improving pre-natal and maternal care. SICA (ACP and Mediterranean Partner Countries)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

4

Other Actions across the Health Theme

Coordination and Support Actions across the Theme

  • Reinforcing the network of National Contact Points (NCP) for the Seventh Framework Programme under Health Theme by promoting transnational co-operation.)

  • Promoting participation of high-technology research intensive SMEs, operating in the biomedical engineering and other medical technology sectors´relevant to Health Theme.

  • Assessment and valorisation of project outcome for hightechnology and research intensive SME participating to Framework Programmes of Research in the healthcare sector.

  • Science communication actions.

  • Initiatives to foster dialogue and debate on health research issues of interest to the public.

  • Studies on the impact of EU legislation on health research and related developments and applications.

  • 2.call:

  • Promotion and facilitation of international cooperation in areas relevant to the objectives of this theme. (SICA, ICPC)

    Responding to EU policy needs (2.call)

  • Paediatric medicinal products, Drug safety research, Living and work conditions, Health statistics, Tobacco Control


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Example „Innovative Medicines“ - en route to a „Joint Technology Initiative“

  • Accelerated Development of safe and more effective medicines

  • Revitalization of the the biopharmaceutical research and development (R&D) environment for Europe to become more competitive

  • Improving the collaboration between all relevant actors from public and private organisations (public-private partnerships)

  • Draft and Implementation of a European Research Agenda:

    Second version of the Strategic Research Agenda published recently

    • First Calls expected for end of2007/beginning of 2008

    • http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed

    • http://rp7.ffg.at/RP7.aspx_param_target_is_116120.v.aspx


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

« Innovative Medicines »

2. version of the « Strategic Research Agenda »:

4 main topics:

  • Safety:

    Early safety evaluation and risk assessment, creation of a European Centre for Drug Safety

  • Efficacy:

    Predictive pharmacology, biomarker identification and validation, patient recruitment and risk assessment

  • Knowledge Management:

    New technologies to control and analyse enormous quantities of information in an integrative and predictive way

  • Education and Training:

    Bridge gaps in expertise required to strengthen the biopharmaceutical R&D process, creation of a European Medicines Research Academy


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Technologieplattform

« Innovative Medicines »

  • Contact in Austria:

    Univ. Prof. Dr. Hans Georg Eichler,

    Vice Rector of the Medical University in Vienna

    [email protected]


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

  • Thema 2- Lebensmittel, Landwirtschaft,

  • Fischerei und Biotechnologie

  • (1.935 Mio Euro)

    Ziel:

  • Aufbau einer “wissensgestützten Bio-Wirtschaft”

    Schwerpunkte:

  • Sicherere, gesündere und hochwertigere Lebensmittel

  • Tierschutz

  • Nachhaltige Produktion und Verwendung nachwachsender Bio-Rohstoffe

  • Epizoonosen und Zoonosen

  • Lebensmittelbedingte Dysfunktionen

  • Nachhaltigkeit und Sicherheit der landwirtschaftlichen Erzeugung und der Fischerei


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Nachhaltige Erzeugung und Bewirtschaftung der biologischen Ressourcen aus Böden, Wäldern und der aquatischen Umwelt

2

“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit

und Wohlergehen

3

Biowissenschaften und Biotechnologie im Dienste nachhaltiger Non-food-Erzeugnisse und Verfahren

Thema 2- Lebensmittel, Landwirtschaft,

Fischerei und Biotechnologie


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

1

Nachhaltige Erzeugung und Bewirtschaftung der biologischen Ressourcen aus Böden, Wäldern und der aquatischen Umwelt

  • Development of new tools and processes to support R&D in crop plants: molecular breeding

  • Mining genomics information of farm animals to generate new information on the genetic basis of phenotypes important to sustainable animal production

  • Development of genetic systems for crop improvement through a systems biology approach

  • Development of technologies and tools for the exploitation of livestock genome

  • Using new technologies to identify (re-)emerging pathogens from wildlife reservoirs

  • Annual food crops with improved tolerance to multiple abiotic stresses

  • Genomics for cereal improvement for food, feed and non-food uses

  • Development of more efficient risk analysis techniques for pests and pathogens of phytosanitary concern

  • Reducing the need for external inputs in high-value protected horticultural and ornamental crops

  • Developing new methods for valuing and marketing of currently non-marketable forest goods and services

  • Coordination of Agricultural Research in the Mediterranean

  • Reduction of N excretion in ruminants

  • From capture based to self-sustained aquaculture

  • Breeding tools for improved livestock products

  • The farm of tomorrow

  • GMO cost-effective and crop-specific co-existence measures

  • (...)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

2

“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit

und Wohlergehen

  • Smart control for improved food and feed technologies (Large collaborative project)

  • Assessment and improvement of existing food and feed technologies (Small collaborative project)

  • Nano-devices for quality assurance, food safety and product properties(Small collaborative projects)

  • Exposure to food additives, flavourings, and migrants coming from food contact materials – dietary intake models (Large collaborative project)

  • Innovative and safe packaging (Small collaborative project)

  • Post Market Monitoring of the effect of GM food and feed on human and animal health (Small collaborative project)

  • Converging technologies and their potential for the food area (Small collaborative project)

  • Detecting contaminants in the Food and Feed Chain

  • (…)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

3

Biowissenschaften und Biotechnologie im Dienste nachhaltiger Non-food-Erzeugnisse und Verfahren

  • ENGERGY PLANTS – Novel plants for energy production (Small collaborative project)

  • GREEN OIL: Plants providing oils for the future (Large collaborative project)

  • BIO-VET-Pharming: Plant made recombinant pharmaceuticals for animals (Network of Excellence)

  • FOREST PRODUCTS – New forest based products and processes (Large collaborative project)

  • GREEN FACTORY – The expression and accumulation of valuable industrial compounds in plants (Large collaborative project)

  • Improved Microbes – Metabolic engineering and modelling (Coordination and Support Action)

  • IMPROVED MICROBES for the Environment – Microbial gene expression under conditions of stress (Large collaborative project)

  • ANIMAL BY PRODUCTS - Nove methods of treatment of animal by products for the production of substances with biologically valuable functional properties (Small collaborative project)

  • And many more….


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Plants for the Future:

http://www.epsoweb.org/Catalog/TP/index.htm

Food for Life:

http://etp.ciaa.be/asp/home/welcome.asp

Global Animal Health:

http://www.ifahsec.org/Europe/EUPlatform/Platform.htm

Farm Animal Breeding and Reproduction:

http://www.fabretp.org/

EuropäischeTechnologie-Plattformen im Bereich Lebensmittel, Landwirtschaftund Biotechnologie


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Information and Communication Technologies:

Objective ICT-2007.5.3: Virtual Physiological Human

Nanosciences, Nanotechnologies, Materials and new Production

Technologies:

„Creation of a critical and commented database on the health,

safety and environmental impact of nanoparticles“

„Process intensification in chemicals production“

„Substantial innovation in the European medical industry: development of

nanotechnology-based systems for in-vivo diagnosis and therapy (in

Coordination with topic HEALTH-2007-2.4.1-7 and HEALTH-2007-1.2-3 in

Theme 1 "Health")

Weitere relevante Themen der 1.Ausschreibung aus anderen Bereichen


Inhalt3

Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung

Das Programm „IDEAS“

Inhalt


Das programm ideas ein berblick

Medizinische Universität Graz

Das Programm IDEAS– ein Überblick

  • Ziele des Spezifischen Programms IDEAS

  • Rolle des European Research Council (ERC)

  • Förderlinien


Worum geht es beim spezifischen programm ideas

Medizinische Universität Graz

Worum geht es beim Spezifischen Programm IDEAS?

  • Grundlagenorientierte Spitzenforschung (Pionierforschung)

  • Alle Forschungsbereiche

  • Umsetzung durch European Research Council ERC


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Medizinische Universität Graz

  • Forschung an den Grenzen des Wissens (Pionierforschung)

    • riskant

    • interdisziplinär

    • schwer voraussagbar in ihrer praktischen Anwendung

  • Vermeidung unzeitgemäßer Unterscheidungen:

    • Grundlagenforschung - angewandte Forschung

    • Wissenschaft -Technologie

    • traditionelle Disziplinen


Wozu pionierforschung

Medizinische Universität Graz

Wozu Pionierforschung?


Welche rolle spielt der erc

Medizinische Universität Graz

Welche Rolle spielt der ERC?

Mittel des spezifischen Programms IDEAS werden für die Aktivitäten des European Research Council (ERC)eingesetzt

  • Hebelwirkung -> strukturelle Verbesserung im Europäischen Forschungssystem

  • Erhöhung der Exzellenz, Dynamik und Kreativität im Bereich Grundlagenforschung

  • Stärkung vorhandener Potentiale “an den Grenzen des Wissens”

  • EinzigesEvaluierungskriterium: EXZELLENZ


Erc struktur und organisation

Medizinische Universität Graz

ERC – Struktur und Organisation

  • Forschungsrat (Scientific Council)

    • Unabhängige Festlegung der ERC-Strategie, wissenschaftlicher Zielsetzungen, Abwicklung

    • Unterstützt durch Agentur (Dedicated Implementation Structure)

  • Agentur (Dedicated Implementation Structure)

    • Praktische Implementierung und operatives Management

  • Europäische Kommission

    • stellt die finanziellen Mittel zur Verfügung

    • sorgt für Autonomie des ERC


Erc wissenschaftliche schwerpunkte

Medizinische Universität Graz

ERC - Wissenschaftliche Schwerpunkte

  • Physikalische und technische Wissenschaften

  • Lebenswissenschaften

  • Sozial- und Geisteswissenschaften


Erc panels

Medizinische Universität Graz

ERC– Panels

  • 20 Scientific Panels

  • 20 Panel-Vorsitzende(International anerkannte WissenschafterInnen und ForscherInnen)

  • 200 Panel-Mitglieder(WissenschafterInnen und ForscherInnen aus den jeweiligen Fachgebieten)

  • 1000 - 2000 GutacherInnen

    (Consultation letter an Europäische Forschungsorganisationen)


Welche f rderschienen gibt es

Medizinische Universität Graz

Welche Förderschienen gibt es?

  • ERC Starting Independent Researchers Grants(ERC Starting Grant)

  • ERC Advanced Investigator Grants(ERC Advanced Grant)


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Medizinische Universität Graz

  • ERC Starting Grants

  • Unterstützt werden exzellente Forschende aller Nationalitäten, die ihr erstes selbständiges ForscherInnen-Team in Europa etablieren wollen. Der Weg in die Unabhängigkeit wird unterstützt

    • Ausschreibung: 22. Dezember 2006

    • Einreichfrist: April 2007 für die erste Stufe

  • ERC Advanced Grants

  • Für exzellente ForscherInnen und WissenschafterInnen, die bereits eine gewisse Unabhängigkeit erlangt haben -> als Folgeprogramm des “Starting Grants” zu verstehen

    • Ausschreibung: Sommer 2007

    • Einreichfrist: Anfang 2008


Erc starting grants

Medizinische Universität Graz

ERC Starting Grants

  • Projektvorschläge werden von einzelnem/r Forscher/in (“Principal investigator”) eingereicht.

  • Durchführung der Projekte: transnationale oder nationale Teams

  • Teamleiter: jede Nationalität

    befindet sich in einer Forschungseinrichtung in Europa (EU25, Kandidatenländer, assoziierte Länder)

  • Teammitglieder: jede Nationalität

  • Verträge werden zwischen dem ERC und der Gasteinrichtung des Teamleiters abgeschlossen, die für das unabhängige Arbeiten des Teams garantieren muß.


Erc starting grants wer reicht ein

Medizinische Universität Graz

ERC Starting Grants - wer reicht ein?

  • TeamleiterIn (“Principal Investigator”)

    • Über 2, weniger als 8 Jahre Forschungserfahrung nach Abschluß des Doktorats.

    • Teamleiter darf nur in einem Starting Grant – Projekt tätig sein.

    • Keine Beschränkungen bei der Wahl der Projektinhalte.

    • Es muß das erste unabhängige Team sein.

    • Fähigkeit, eigenes Team zu etablieren.


Erc starting grants evaluierungskriterien

Medizinische Universität Graz

ERC Starting Grants - Evaluierungskriterien

  • Principal Investigator: Potential to become a world class research leader

    • Quality of research output

    • Intellectual capacity and creativity

  • Quality of the proposed research project

    • Ground-breaking nature of the research

    • Potential impact

    • Methodology

  • Research Environment

    • Transition to independence

    • Host institution (normally applicant legal entity)

    • Participation of other legal entities


Erc weitere information

Medizinische Universität Graz

ERC – weitere Information

Kontakt:

  • Ralf König

  • [email protected]

  • +43 (0)57755 - 4601

  • http://rp7.ffg.at/erc

  • http://rp7.ffg.at/erc

  • http://erc.europa.eu

  • http://cordis.europa.eu/fp7/ideas.htm

  • http://ec.europa.eu/research/future/index_en.cfm


Ihre f rderm glichkeiten im 7 eu rahmenprogramm 7 rp f r forschung und entwicklung ylva huber

Vielen Dank für Ihre Aufmerksamkeit&viel Erfolg für Ihre Projekte im 7. Rahmenprogramm!


  • Login